Pharmaceutical

Arbor to advance gene editing treatments with $73.9m funding

Arbor Biotechnologies has closed $73.9m for its gene editing therapeutic pipeline aimed at liver and central nervous system diseases.

Mar 19, 2025 - 06:00
Arbor to advance gene editing treatments with $73.9m funding
Arbor Biotechnologies has closed $73.9m for its gene editing therapeutic pipeline aimed at liver and central nervous system diseases.
Read the original article

Tags:

Previous Article

Revolutionizing Chemical Analysis: FSU Chemists Harness Machine Learning and Rob...

Next Article

Opko and Entera focus on oral care for obesity and metabolic disorders

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process

STAT+: Sen. Cassidy wants to put a stop to FDA delays i...

Jun 8, 2023

Allogeneic cell therapies “poised for prime time” says expert

Allogeneic cell therapies “poised for prime time” says ...

Mar 21, 2025

STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started

STAT+: Scientists have mapped the human brain in unprec...

Oct 12, 2023